rope01 rope02

Careers

We are building a diverse team of talented people with a singular focus on bringing promising and new cancer therapies to patients.

Mission & Vision

Turning Point Therapeutics is using novel science to address one of the greatest medical challenges of our time, developing cancer therapies to overcome the resistance inherent in other approved cancer medicines. Our team is passionate about changing the course of care for patients.

Our Culture

Our culture is best expressed through the diverse voices of our employees.

  • – Denise, Biostatistics

    “The work is fast-paced and I like that everyone understands it is essential.”

  • – Zach, Clinical Development

    “I’m proud to be part of a collaborative team of highly talented people working passionately to bring innovative therapies to patients.”

  • – Jessica, Clinical Operations

    “We are hiring talented people and giving them space to do great work. We all share the burden and challenge to help change the course of treatment for cancer patients.”

  • – John, Finance

    “You get the sense here that we are all building this company, whether you are discovering or developing a new therapy, or helping it all run efficiently.”

Opportunities

Are you interested in joining us on our journey? Explore our career opportunities today.

Turning Point Therapeutics’ CEO To Present At Goldman Sachs 40th Annual Global Healthcare Conference

06/04/2019/by Lauren Fish

Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer

05/31/2019/by David Anderson

Turning Point Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TPX-0022, A Novel MET/CSF1R/SRC Inhibitor

05/15/2019/by Lauren Fish

Turning Point Therapeutics Names Biotech Veteran Patrick Machado J.D. to its Board of Directors

05/14/2019/by eallison

Turning Point Therapeutics and Almac Diagnostic Services Announce Approval of an Investigational Device Exemption for the Companion Diagnostic Assay to the Registrational TRIDENT-1 Clinical Study

05/06/2019/by Lauren Fish

Turning Point Therapeutics Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares

04/22/2019/by David Anderson

Turning Point Therapeutics Announces Pricing of Initial Public Offering

04/16/2019/by David Anderson

Turning Point Therapeutics Appoints Annette North as Executive Vice President and General Counsel

04/08/2019/by David Anderson

Turning Point Therapeutics’ Kinase Inhibitors Show High Potency against Targeted Oncogene Drivers and Their Mutations

04/01/2019/by David Anderson

Turning Point Therapeutics Appoints Jim Mazzola to Lead Corporate Communication and Investor Relations

03/25/2019/by David Anderson

Turning Point Therapeutics Files Registration Statement for Proposed Initial Public Offering

03/21/2019/by David Anderson

Turning Point Therapeutics to Present Data from Four Studies at AACR Annual Meeting

02/27/2019/by David Anderson

test

TRIDENT-1

02/21/2019/by David Anderson

Turning Point Therapeutics Appoints Dr. Robert Xin as Senior Vice President of Clinical Development

01/28/2019/by David Anderson

Turning Point Therapeutics Mourns the Death of Board Member Lewis Shuster

12/17/2018/by David Anderson

Turning Point Therapeutics Appoints Jacob Chacko, M.D., to its Board of Directors

11/28/2018/by David Anderson

TP Therapeutics and Almac Diagnostic Services Enter into Agreement to Develop Next-Generation Sequencing Pan-Cancer Companion Diagnostic

10/24/2018/by David Anderson

TP Therapeutics Completes $80 Million Mezzanine Financing Co-Led by Foresite Capital and venBio Partners

10/19/2018/by David Anderson

TP Therapeutics Announces Updated Interim Phase 1/2 Clinical Trial Data of Repotrectinib (TPX-0005) in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer Patients at 19th World Conference on Lung Cancer

09/24/2018/by David Anderson

TP Therapeutics Announces Updated Interim Phase 1 Data with Repotrectinib (TPX-0005) in ROS1 Fusion-positive NSCLC to be Presented at World Conference on Lung Cancer

09/05/2018/by David Anderson

Cancer Discovery Highlights Potent Effects of TP Therapeutics’ Novel, Lead Investigational Compound Repotrectinib in Tumors Harboring ROS1, TRK or ALK Fusions with Solvent Front Mutations

08/10/2018/by David Anderson

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 Study

06/04/2018/by David Anderson

TP Therapeutics Announces Phase 1 Data of Ropotrectinib (TPX-0005) to be Presented at the Annual American Society of Clinical Oncology Meeting

05/17/2018/by David Anderson

TP Therapeutics Appoints Athena Countouriotis, M.D., as EVP and Chief Medical Officer

05/14/2018/by David Anderson

TP Therapeutics Appoints Sheila K. Gujrathi, MD to Board of Directors and as a Strategic Advisor

12/04/2017/by David Anderson

TP Therapeutics Announces FDA Orphan Drug Designation Granted to TPX-0005 for Treatment of Non-Small Cell Lung Adenocarcinomas Harboring ALK, ROS1, or NTRK Oncogenic Rearrangements

06/27/2017/by David Anderson

TP Therapeutics Closes $45M Series C Financing

05/23/2017/by David Anderson

TP Therapeutics Raises Nearly $18 Million in Series B Financing Round

05/23/2016/by David Anderson